HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

Francesco Bussu; Luca Tagliaferri; Giancarlo Mattiucci; Claudio Parrilla; Davide Rizzo; Maria Antonietta Gambacorta; Valentina Lancellotta; Rosa Autorino; Carla Fonnesu; Caterina Kihlgren; Jacopo Galli; Gaetano Paludetti; György Kovács; Vincenzo Valentini

doi:10.1002/hed.25646

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

Francesco Bussu, Luca Tagliaferri^*, Giancarlo Mattiucci, Claudio Parrilla, Davide Rizzo, Maria Antonietta Gambacorta, Valentina Lancellotta, Rosa Autorino, Carla Fonnesu, Caterina Kihlgren, Jacopo Galli, Gaetano Paludetti, György Kovács, Vincenzo Valentini

^*Corresponding author for this work

Clinic of Radiotherapy

7 Citations (Scopus)

Abstract

Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.

Original language	English
Journal	Head and Neck
Volume	41
Issue number	6
Pages (from-to)	1667-1675
Number of pages	9
ISSN	1043-3074
DOIs	https://doi.org/10.1002/hed.25646
Publication status	Published - 06.2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.25646

Cite this

Bussu, F., Tagliaferri, L., Mattiucci, G., Parrilla, C., Rizzo, D., Gambacorta, M. A., Lancellotta, V., Autorino, R., Fonnesu, C., Kihlgren, C., Galli, J., Paludetti, G., Kovács, G., & Valentini, V. (2019). HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies. Head and Neck, 41(6), 1667-1675. https://doi.org/10.1002/hed.25646

@article{be52c92a72ea4eab868d461fa9cd0c23,

title = "HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies",

abstract = "Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.",

author = "Francesco Bussu and Luca Tagliaferri and Giancarlo Mattiucci and Claudio Parrilla and Davide Rizzo and Gambacorta, {Maria Antonietta} and Valentina Lancellotta and Rosa Autorino and Carla Fonnesu and Caterina Kihlgren and Jacopo Galli and Gaetano Paludetti and Gy{\"o}rgy Kov{\'a}cs and Vincenzo Valentini",

year = "2019",

month = jun,

doi = "10.1002/hed.25646",

language = "English",

volume = "41",

pages = "1667--1675",

journal = "Head and Neck",

issn = "1043-3074",

number = "6",

}

Bussu, F, Tagliaferri, L, Mattiucci, G, Parrilla, C, Rizzo, D, Gambacorta, MA, Lancellotta, V, Autorino, R, Fonnesu, C, Kihlgren, C, Galli, J, Paludetti, G, Kovács, G & Valentini, V 2019, 'HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies', Head and Neck, vol. 41, no. 6, pp. 1667-1675. https://doi.org/10.1002/hed.25646

TY - JOUR

T1 - HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

AU - Bussu, Francesco

AU - Tagliaferri, Luca

AU - Mattiucci, Giancarlo

AU - Parrilla, Claudio

AU - Rizzo, Davide

AU - Gambacorta, Maria Antonietta

AU - Lancellotta, Valentina

AU - Autorino, Rosa

AU - Fonnesu, Carla

AU - Kihlgren, Caterina

AU - Galli, Jacopo

AU - Paludetti, Gaetano

AU - Kovács, György

AU - Valentini, Vincenzo

PY - 2019/6

Y1 - 2019/6

N2 - Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.

AB - Background: Interventional radiotherapy (brachytherapy; IRT) reemerged in the last decades as a potentially useful tool in head and neck oncology after a set of clear technical improvements were developed. Methods: Sixty-one high dose ratio (HDR) IRT treatments were recommended and performed on 58 patients. We classified the cases into four relatively homogeneous groups based on the clinical needs that led to the recommended IRT. Also, we separately evaluated primary and recurrent cases. Results: Disease-specific survival was significantly different among the four treatment groups. The group with the best prognosis was the cohort treated locally by exclusive interstitial IRT for resectable midface malignancies (2-year relapse-free survival = 82%, disease-specific survival = 89%). Conclusion: HDR IRT is a valuable tool in well-defined clinical situations and, in particular, in recurrences. In midface malignancies, it could become the preferred primary treatment.

UR - http://www.scopus.com/inward/record.url?scp=85060975692&partnerID=8YFLogxK

U2 - 10.1002/hed.25646

DO - 10.1002/hed.25646

M3 - Journal articles

C2 - 30701614

AN - SCOPUS:85060975692

SN - 1043-3074

VL - 41

SP - 1667

EP - 1675

JO - Head and Neck

JF - Head and Neck

IS - 6

ER -

HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this